Split dose versus single bolus gadolinium administration in ecv calculation at 3 tesla cmr
- 331 Downloads
KeywordsCardiovascular Magnetic Resonance Contrast Administration Single Bolus Cardiovascular Magnetic Resonance Study Split Dose
Diffuse myocardial fibrosis may be quantified with cardiovascular magnetic resonance (CMR) by calculating extra-cellular volume (ECV) from native and post-contrast T1 values. Previous studies have used either infusion or single bolus contrast administration. In clinical practice however split dose contrast injection is used as part of a stress/rest protocol in stress perfusion studies. The effects of using such an injection regime on ECV calculation is unknown.
This study aimed to assess the effects of split dose versus single bolus contrast administration on ECV calculation.
Ten healthy volunteers were studied on a 3.0 Tesla (Philips Achieva TX) MR system and underwent three separate CMR studies over a mean of 30 days. In one study, contrast was administered as a single bolus (Gadovist 0.15mmol/kg). In two further CMR studies, contrast was given in two boluses (0.075mmol/kg per bolus) as part of an adenosine stress/rest perfusion protocol, separated by 12 minutes. T1 maps were acquired pre contrast and 15 minutes following the single bolus or second contrast injection. T1 measurements were made in the inter-ventricular septum. Means and standard deviations were compared between MOLLI T1 estimates and ECV calculated.
ECV quantification using split dose contrast administration is reproducible and in healthy controls agrees well with previously validated methods. This suggests that perfusion CMR studies may incorporate assessment of tissue composition by ECV based on T1 mapping.
AKM is funded by a British Heart Foundation Project Grant (PG/14/10/30641)
DAB has a Research Doctoral Fellowship from the National Institute for Health and Research (DRF-2012-05-155)
SP is funded by a British Heart Foundation Senior Fellowship (FS/10/62/28409).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.